drugset / Trial / NCT00003102
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Phase 1/2
Completed
15 enrolled
Ludwig Institute for Cancer Research
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients with advanced kidney cancer.
Timeline
- Start
- 1998-11-17
- Primary completion
- 2000-04-19
- Completion
- 2003-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | girentuximab | Monoclonal antibody | 5 mg | Intravenous |